Acknowledging the small sample size, the OS benefit with BR–pola was seen irrespective of age, refractoriness to last therapy, number of prior therapies, prior AHCT, DLBCL subtype based on COO by GEP, or MYC/BCL2 double-expression status. Here, BCL2 is linked to diffuse large B-cell lymphoma.